^
BIOMARKER:

MYC overexpression + BCL2 overexpression

i
Other names: MYC rearrangement-BCL2 rearrangement
Entrez ID:
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
Lymphoma Hub - 3 weeks
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: B - Late Trials
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
EPOCH-R
Sensitive: C3 – Early Trials
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
doxorubicin hydrochloride + chidamide
Sensitive: D – Preclinical
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
CG-806
Sensitive: D – Preclinical
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
venetoclax + CG-806
Sensitive: D – Preclinical